Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer

Epigenomics

Volumn 8, Issue 8, 2016, Pages 1079-1085

  Reid, Glen ^a,b   Kao, Steven C ^a,b,c   Pavlakis, Nick ^d,e   Brahmbhatt, Himanshu ^f   MacDiarmid, Jennifer ^f   Clarke, Stephen ^d,e   Boyer, Michael ^b,c   Van Zandwijk, Nico ^a,b  

^a Asbestos Diseases Research Institute   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Chris O'Brien Lifehouse ^*  (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

^f Engeneic Ltd   (Australia)

Author keywords

EDVs; malignant pleural mesothelioma; mesomiR 1; miR 16; miRNA; targeted delivery

Indexed keywords

MICRORNA;

ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THORAX DISEASE; LUNG NEOPLASMS; MESOTHELIOMA; PROCEDURES; RNAI THERAPEUTICS; THORACIC NEOPLASMS;

CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; RNAI THERAPEUTICS; THORACIC NEOPLASMS;

EID: 84983356775     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi-2016-0035     Document Type: Article

References (44)

1. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu. Rev. Med. 60 167-179 (2009).
2. Bichi R, Shinton SA, Martin ES et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc. Natl Acad. Sci. USA 99(10), 6955-6960 (2002).
3. Lee YS, Dutta A. MicroRNAs in cancer. Annu. Rev. Pathol. 4, 199-227 (2009).
4. Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 11(12), 849-864 (2011).
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
6. Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature 435(7043), 834-838 (2005).
7. Henry JC, Azevedo-Pouly AC, Schmittgen TD. MicroRNA replacement therapy for cancer. Pharm. Res. 28(12), 3030-3042 (2011).
8. Akao Y, Nakagawa Y, Hirata I et al. Role of anti-oncomirs miR-143 and -145 in human colorectal tumors. Cancer Gene Ther. 17(6), 398-408 (2010).
9. Ibrahim AF, Weirauch U, Thomas M, Grunweller A, Hartmann RK, Aigner A. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res. 71(15), 5214-5224 (2011).
10. Reid G, Pel ME, Kirschner MB et al. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann. Oncol. 24(12), 3128-3135 (2013).
11. Trang P, Medina PP, Wiggins JF et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene 29(11), 1580-1587 (2010).
12. Wiggins JF, Ruffino L, Kelnar K et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 70(14), 5923-5930 (2010).
13. Zhao J, Kelnar K, Bader AG. In-depth analysis shows synergy between erlotinib and miR-34a. PLoS ONE 9(2), e89105 (2014).
14. Fortunato O, Boeri M, Verri C, Moro M, Sozzi G. Therapeutic use of microRNAs in lung cancer. Biomed. Res. Int. 2014, 756975 (2014).
15. Johnson SM, Grosshans H, Shingara J et al. RAS is regulated by the let-7 microRNA family. Cell 120(5), 635-647 (2005).
16. Johnson CD, Esquela-Kerscher A, Stefani G et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 67(16), 7713-7722 (2007).
17. Esquela-Kerscher A, Trang P, Wiggins JF et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 7(6), 759-764 (2008).
18. Bader AG. miR-34 - a microRNA replacement therapy is headed to the clinic. Front. Genet. 3, 120 (2012).
19. Trang P, Wiggins JF, Daige CL et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther. 19(6), 1116-1122 (2011).
20. Wu Y, Crawford M, Mao Y et al. Therapeutic delivery of microRNA-29b by cationic lipoplexes for lung cancer. Mol. Ther. Nucleic Acids 2 e84 (2013).
21. Cortez MA, Valdecanas D, Zhang X et al. Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. Mol. Ther. 22(8), 1494-1503 (2014).
22. Kasinski AL, Kelnar K, Stahlhut C et al. A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene 34(27), 3547-3555 (2015).
23. Birnie KA, Yip YY, Ng DC et al. Loss of miR-223 and JNK signaling contribute to elevated stathmin in malignant pleural mesothelioma. Mol. Cancer Res. 13(7), 1106-1118 (2015).
24. Kirschner MB, Cheng YY, Badrian B et al. Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. J. Thorac. Oncol. 7(7), 1184-1191 (2012).
25. Bonci D, Coppola V, Musumeci M et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat. Med. 14(11), 1271-1277 (2008).
26. Bandi N, Zbinden S, Gugger M et al. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res. 69(13), 5553-5559 (2009).
27. Cimmino A, Calin GA, Fabbri M et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl Acad. Sci. USA 102(39), 13944-13949 (2005).
28. Williams M, Kirschner MB, Cheng YY et al. miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. Oncotarget 6(27), 23480-23495 (2015).
29. Ueno T, Toyooka S, Fukazawa T et al. Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma. Acta Med. Okayama 68(1), 23-26 (2014).
30. Finnerty JR, Wang WX, Hebert SS, Wilfred BR, Mao G, Nelson PT. The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases. J. Mol. Biol. 402(3), 491-509 (2010).
31. Reid GWM, Kirschner Mb, Mugridge N et al. Targeted delivery of a synthetic microRNA-based mimic as an approach to cancer therapy. Cancer Res. 75(Suppl. 15), Abstract 3976 (2015).
32. MacDiarmid JA, Mugridge NB, Weiss JC et al. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell 11(5), 431-445 (2007).
33. MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J et al. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat. Biotechnol. 27(7), 643-651 (2009).
34. Glover AR, Zhao JT, Gill AJ et al. microRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma. Oncotarget 6(34), 36675-36688 (2015).
35. Beg MS, Brenner A, Sachdev J et al. Safety, tolerability, and clinical activity of MRX34, the first-in-class liposomal miR-34 mimic, in patients with advanced solid tumors. Presented at: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Boston, MA, USA, 5-9 November 2015.
36. Solomon BJ, Desai J, Rosenthal M et al. A first-time-inhuman Phase I clinical trial of bispecific antibody-targeted, paclitaxel-packaged bacterial minicells. PLoS ONE 10(12), e0144559 (2015).
37. Whittle JR, Lickliter JD, Gan HK et al. First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma. J. Clin. Neurosci. 22(12), 1889-1894 (2015).
38. Kao SC, Fulham M, Wong K et al. A significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma. Am. J. Respir. Crit. Care Med. 191(12), 1467-1469 (2015).
39. Bernardo BC, Gao XM, Tham YK et al. Silencing of miR-34a attenuates cardiac dysfunction in a setting of moderate, but not severe, hypertrophic cardiomyopathy. PLoS ONE 9(2), e90337 (2014).
40. Bernardo BC, Gao XM, Winbanks CE et al. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc. Natl Acad. Sci. USA 109(43), 17615-17620 (2012).
41. Alley EW ML, Santoro A, Beckey K et al. Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: preliminary results from KEYNOTE-028. Cancer Res. 75(Suppl. 15), Abstract CT103 (2015).
42. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373(17), 1627-1639 (2015).
43. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373(2), 123-135 (2015).
44. Cortez MA, Ivan C, Valdecanas D et al. PDL1 regulation by p53 via miR-34. J. Natl Cancer Inst. 108(1), djv303 (2016).